All In Biotech

Drug Trial Radar · NCT07515872

Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

May 31, 2027

Study completion May 31, 2028

Sponsor

Lead sponsor
ZetrOZ, Inc.Industry
Sponsor type
Industry
First posted
Apr 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the ability of long-duration high-frequency continuous-wave therapeutic ultrasound to alleviate knee Osteoarthritis pain over an 12-week period. The primary objective of this study is to evaluate the analgesic effect of ultrasound treatment in subjects suffering from knee Osteoarthritis pain. Secondary objectives are to assess the ability of ultrasound treatment to improve joint function.

Conditions

  • Arthritis
  • Osteo Arthritis of the Knee

Interventions

  • Sustained Acoustic Device with 2.5% Diclofenac PatchDevice

    Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.

  • Sustained Acoustic Device with 0% Diclofenac PatchDevice

    Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.

  • Intra articular injectionDrug

    Single intraarticular injection of 1cc 40mg/cc triamcinolone acetonide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From BaselineTime frame: Through study completion, average of 12 weeks
  2. Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Time frame: Through study completion, average of 12 weeks.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Orthopaedic Foundation

    Stamford, Connecticut

  • Cayuga Medical Center - Medical Pain Consultants

    Dryden, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.